You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Isolate and Patient Characteristics for 300 Veterans who had Staphylococcus aureus bacteremia
at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 2.  

Infection Characteristics for 300 Veterans who had Staphylococcus aureus Bacteremia
at 4 Veterans Affairs Medical Centers, USA, 2004–2008

Table 3.  

Patient and Infection Characteristics for 300 Veterans with Staphylococcus aureus Bacteremia
and Association with Illicit Drug Use at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 4.  

Patient and Infection Characteristics for 300 Veterans with Staphylococcus aureus Bacteremia
and Association with USA300 MRSA at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 5.  

Independent Risk Factors for USA300 MRSA Bacteremia
Among 300 Veterans at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

CME

Illicit Drug Use and the Risk of USA300 Methicillin-Resistant Staphylococcus aureus Infections With Bacteremia

  • Authors: Kristen M. Kreisel, PhD; J. Kristie Johnson, PhD; O. Colin Stine, PhD; Michelle D. Shardell, PhD; Alan J. Lesse, MD; Fred M. Gordin, MD; Michael W. Climo, MD; Mary-Claire Roghmann, MD, MS
  • CME Released: 8/16/2010
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/16/2011
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care clinicians, infectious disease specialists, and other specialists who care for patients at risk for community-acquired MRSA infection.

The goal of this activity is to review the epidemiology of community-acquired MRSA and its changing pattern of acquisition.

Upon completion of this activity, participants will be able to:

  1. Examine the association of illicit drug use with USA300 MRSA infection, including risk factors for acquisition and transmission
  2. Describe characteristics of illicit drug users who acquire MRSA and the changing pattern of risk from 2004 to 2008 in the United States with implications for management and prevention


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • J. Kristie Johnson, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: J. Kristie Johnson, PhD, has disclosed the following relationships:
    Received grants for clinical research from: Becton, Dickinson and Company

  • O. Colin Stine, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: O. Colin Stine, PhD, has disclosed no relevant financial relationships.

  • Michelle D. Shardell, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: Michelle D. Shardell, PhD, has disclosed no relevant financial relationships.

  • Eli N. Perencevich, MD, MS

    University of Maryland, Baltimore, Maryland; VA Maryland Health Care System, Baltimore, Maryland

    Disclosures

    Disclosure: Eli N. Perencevich, MD, MS, has disclosed the following relationships:
    Received grants for clinical support from: Pfizer Inc.

  • Alan J. Lesse, MD

    VA Western New York Healthcare System, Buffalo, New York; University at Buffalo, Buffalo, New York

    Disclosures

    Disclosure: Alan J. Lesse, MD, has disclosed no relevant financial relationships.

  • Fred M. Gordin, MD

    Washington DC VA Medical Center, Washington, DC; George Washington University, Washington, DC

    Disclosures

    Disclosure: Fred M. Gordin, MD, has disclosed no relevant financial relationships.

  • Michael W. Climo, MD

    Hunter Holmes McGuire VA Medical Center, Richmond, Virginia; Medical College of Virginia at Virginia Commonwealth University, Richmond, Virginia

    Disclosures

    Disclosure: Michael W. Climo, MD, has disclosed the following relationships:
    Served as an advisor or consultant for: Biosynexus Incorporated
    Received grants for clinical research from: Biosynexus Incorporated

  • Mary-Claire Roghmann, MD, MS

    University of Maryland, Baltimore, Maryland; VA Maryland Health Care System, Baltimore, Maryland

    Disclosures

    Disclosure: Mary-Claire Roghmann, MD, MS, has disclosed no relevant financial relationships.

Editor(s)

  • Carol Snarey

    Copyeditor, Emerging Infectious Diseases

    Disclosures

    Disclosure: Carol Snarey has disclosed no relevant financial relationships.

CME Author(s)

  • Désirée Lie, MD, MSEd

    Clinical Professor of Family Medicine, Director of Research and Faculty Development, University of California, Irvine at Orange, California

    Disclosures

    Disclosure: Désirée Lie, MD, MSEd, has disclosed the following relevant financial relationship:
    Served as a nonproduct speaker for: "Topics in Health" for Merck Speaker Services

CME Reviewer(s)

  • Sarah Fleischman

    CME Program Manager, Medscape, LLC

    Disclosures

    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

  • Laurie E. Scudder, DNP, NP

    CME Accreditation Coordinator, Medscape, LLC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Illicit Drug Use and the Risk of USA300 Methicillin-Resistant Staphylococcus aureus Infections With Bacteremia

Authors: Kristen M. Kreisel, PhD; J. Kristie Johnson, PhD; O. Colin Stine, PhD; Michelle D. Shardell, PhD; Alan J. Lesse, MD; Fred M. Gordin, MD; Michael W. Climo, MD; Mary-Claire Roghmann, MD, MSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 8/16/2010

Valid for credit through: 8/16/2011

processing....

Abstract and Introduction

Abstract

To assess the association of illicit drug use and USA300 methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, a multicenter study was conducted at 4 Veterans Affairs medical centers during 2004-2008. The study showed that users of illicit drugs were more likely to have USA300 MRSA bacteremia (in contrast to bacteremia caused by other S. aureus strains) than were patients who did not use illicit drugs (adjusted relative risk 3.0; 95% confidence interval 1.9-4.4). The association of illicit drug use with USA300 MRSA bacteremia decreased over time (p = 0.23 for trend). Notably, the proportion of patients with USA300 MRSA bacteremia who did not use illicit drugs increased over time. This finding suggests that this strain has spread from users of illicit drugs to other populations.

Introduction

Infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) are increasing. Outbreaks have been described in a variety of populations, including sports teams, men who have sex with men, prisoners, and children.[1-10] The USA300 MRSA clone has been recognized as the most common strain causing CA-MRSA infections.[11]

CA-MRSA was first reported in illicit drug users in Detroit in 1980.[12] The drug-using population has been identified as a reservoir of CA-MRSA.[13] Because of the repeated injection or inhalation of drugs, the opportunity for a person to cause and spread infection with one's own colonizing strain is multiplied.[13,14] Skin and soft tissue infections are the most common infections in illicit drug users; the USA300 MRSA strain is the cause of up to 75% of these infections.[13-15] Once this strain colonizes or otherwise infects a person, it can then enter the patient's bloodstream and become a potentially life-threatening bloodstream infection.

If admitted to the hospital, illicit drug-using patients with a USA300 MRSA infection complicated by bacteremia serve as a potential reservoir for transmission to other patient populations. This mechanism may be contributing to the replacement of other MRSA strains typically associated with nosocomial infections by USA300 MRSA and may aid this strain in becoming the predominant isolate causing MRSA infections in both healthcare and community settings.[16,17] The objective of this study was to evaluate the association of illicit drug use with USA300 MRSA bacteremia and whether the association is static or has changed over a 5-year period as the USA300 MRSA epidemic has progressed.

Table of Contents

  1. Abstract and Introduction
  2. Methods
  3. Results
  4. Discussion